Incorrect password
evipedia.ai Suggest Edit

Laser Resurfacing for Skin Rejuvenation

Evidence Review created on 05/06/2026 using AI4L / Opus 4.7

Also known as: Laser Skin Resurfacing, Ablative Laser Resurfacing, Fractional Laser Resurfacing, CO2 Laser Resurfacing, Er:YAG Laser Resurfacing, Fractional Photothermolysis, Laser Skin Rejuvenation, Fraxel

Motivation

Laser resurfacing is a clinic-based procedure that uses focused beams of light to remove or heat the upper layers of the skin, prompting the body to grow smoother, firmer replacement tissue. Because it can produce visible improvements in fine lines, sun damage, and uneven texture, it has become a widely used aesthetic intervention among adults seeking to preserve skin appearance as part of a longevity strategy.

The technology has evolved through three decades, beginning with full-field carbon dioxide and erbium lasers in the 1990s and progressing to fractional devices that treat only microscopic columns of tissue at a time. This shift reduced downtime and complications, and recent work has expanded the role of laser resurfacing beyond cosmetic improvement to include reduction in field cancerization risk on sun-damaged skin.

This review examines the current evidence base for laser resurfacing applied to skin rejuvenation — what outcomes are demonstrated in human trials, how ablative and non-ablative platforms compare, where evidence is conflicted or thin, and what practical considerations apply across device choices.

Benefits - Risks - Protocol - Conclusion

A curated set of expert commentary, podcast episodes, and a key academic review giving accessible high-level overviews of laser resurfacing for skin rejuvenation.

Chris Kresser does not appear to have published a piece focused specifically on laser resurfacing for skin rejuvenation, so no item from him is included. Life Extension publishes broadly on skin aging and topical and supplement strategies but does not have a dedicated overview of laser resurfacing as a procedure, so no item from that source is included.

Grokipedia

No dedicated Grokipedia article exists for laser resurfacing as an intervention. Brand- and modality-specific pages (e.g., “Fraxel”, “Photorejuvenation”) exist but do not constitute a primary, dedicated page for the intervention itself.

Examine

No dedicated Examine.com article exists for laser resurfacing. Examine.com focuses primarily on supplements and dietary interventions, with a limited subset of light-based modalities (e.g., red light therapy) covered as standalone topics; ablative and fractional laser resurfacing as cosmetic-procedure-based interventions are outside the site’s typical scope.

ConsumerLab

No dedicated ConsumerLab article exists for laser resurfacing. ConsumerLab.com focuses on independent testing of supplements, foods, and consumer health products (including some at-home red and near-infrared light therapy devices), and does not cover clinic-administered laser resurfacing procedures.

Systematic Reviews

Key systematic reviews and meta-analyses — synthesizing evidence from randomized controlled trials (RCTs, the strongest single-study design for testing an intervention) and other comparative studies — examining laser resurfacing applied to skin rejuvenation, noting that much of the underlying clinical literature is produced or funded by laser device manufacturers (e.g., Solta Medical/Bausch Health, Lumenis, Lutronic, Sciton, Cynosure, Candela) and by professional and academic dermatology and plastic-surgery groups whose members derive direct revenue from performing laser procedures, a conflict of interest that colors the primary evidence base reviewed below.

Mechanism of Action

Laser resurfacing works by delivering precisely tuned beams of monochromatic light to the skin, producing controlled thermal injury that triggers a wound-healing cascade and dermal remodeling. The key steps are:

  • Selective photothermolysis: Different wavelengths are preferentially absorbed by different chromophores (light-absorbing molecules). Water absorbs strongly at 2940 nm (Er:YAG) and 10,600 nm (CO2), allowing these ablative lasers to vaporize the epidermis and superficial dermis. Mid-infrared wavelengths (1410–1550 nm) for non-ablative devices deposit heat into the dermis without breaching the epidermis, while visible-light lasers target hemoglobin or melanin.

  • Fractional photothermolysis: Most modern devices apply energy in arrays of microscopic treatment zones (MTZs, columns of thermal injury surrounded by intact tissue). Sparing surrounding skin shortens recovery and reduces complications such as scarring and pigmentary disturbance compared to full-field ablation.

  • Wound healing cascade: Thermal injury triggers an acute inflammatory phase (within hours), followed by re-epithelialization (1–14 days depending on device class), neocollagenesis (synthesis of new collagen, peaking at 1–6 months), and dermal remodeling that continues for up to 12 months. Heat shock protein expression, fibroblast activation, and growth-factor release (TGF-β (transforming growth factor-beta, a regulator of tissue repair), bFGF (basic fibroblast growth factor, which stimulates fibroblast proliferation), platelet-derived growth factor) drive the response.

  • Collagen and elastin remodeling: Type I and type III procollagen synthesis increases markedly, while matrix metalloproteinase (MMP, enzymes that break down collagen) activity is modulated; the net effect is replacement of disorganized photoaged dermal collagen with organized neocollagen and improved elastin architecture.

  • Epidermal renewal: Ablative resurfacing physically removes photoaged epidermis and atypical keratinocytes (skin cells); fractional devices induce surrounding epidermal turnover. This contributes to improved tone, reduced lentigines (sun-induced pigment spots), and — separately — to reduced field cancerization (precancerous keratinocyte burden).

  • Competing mechanistic views: Some researchers argue that the dermal remodeling effect of non-ablative fractional devices is modest in vivo and that much of the visible improvement reflects epidermal effects and edema rather than durable collagen deposition. Others note that effect size estimates from histology (skin biopsy) and clinical photography do not always agree, raising questions about how much of the observed benefit reflects measurable tissue change versus rater perception.

Because laser resurfacing is a device-based physical intervention rather than a pharmacological compound, classical pharmacological properties (half-life, protein binding, hepatic metabolism) do not apply.

Historical Context & Evolution

Laser resurfacing emerged from the 1980s development of lasers for medical use. The first widely adopted resurfacing platform was the continuous-wave CO2 laser of the early 1990s, followed by short-pulsed CO2 systems that allowed precise vaporization of the epidermis with controlled dermal heating. Early ablative CO2 produced dramatic improvement in deep wrinkles and photodamage but carried meaningful risks of prolonged erythema, hypopigmentation (loss of skin color), scarring, and weeks of downtime. The late 1990s introduced the Er:YAG laser at 2940 nm, which targets water more selectively than CO2 and produces shallower ablation, less thermal coagulation, and faster healing — at the cost of a smaller wrinkle-effacement effect.

A pivotal shift came in 2004, when Manstein, Anderson, and colleagues at the Wellman Center for Photomedicine introduced fractional photothermolysis. By treating only microscopic columns of tissue and leaving surrounding skin intact, fractional devices preserved most of the rejuvenation benefit while dramatically reducing downtime, infection, and pigmentary complications. The first commercial system, Fraxel SR (from Reliant Technologies, later Solta Medical, now part of Bausch Health), launched the same year. Subsequent fractional devices spanned non-ablative (1410–1550 nm, 1927 nm) and ablative (Er:YAG 2940 nm, CO2 10,600 nm) platforms, with thousands of clinical studies examining parameters and indications.

Historical claims for laser resurfacing have been both over- and under-stated. Early CO2 ablative resurfacing was marketed in the late 1990s as a near-universal solution for facial rejuvenation, an enthusiasm later tempered by recognition of the risk of hypopigmentation and prolonged erythema, particularly in higher Fitzpatrick skin types. Conversely, the early non-ablative fractional devices were sometimes dismissed as “spa lasers” with minimal effect, only for subsequent randomized trials and histologic studies to confirm meaningful, if smaller, improvements in collagen density and clinical appearance. The current honest position is that laser resurfacing produces real, dose-dependent dermal remodeling; ablative and non-ablative platforms occupy a continuum of efficacy and recovery; and recent work has begun to position laser resurfacing not only as a cosmetic procedure but also as a tool for reducing the burden of actinic keratoses and non-melanoma skin cancer in heavily sun-damaged skin.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Fine Lines and Periorbital Wrinkles

Laser resurfacing produces measurable, repeatable reduction in periorbital fine lines and crow’s feet across both ablative and fractional non-ablative devices, with effect sizes confirmed in histology (skin biopsy) and standardized clinical scales. The mechanism is dermal collagen remodeling combined with epidermal renewal. Multiple meta-analyses pool evidence from randomized comparative trials. Effect size scales with device aggressiveness — full-field ablative CO2 produces the largest single-treatment improvement, fractional ablative platforms produce moderate-to-large improvement with much shorter recovery, and fractional non-ablative platforms produce smaller-but-meaningful improvement over multiple sessions.

Magnitude: Approximately 25–60% reduction in wrinkle scores on Fitzpatrick wrinkle and elastosis scale (a clinical grading scale for wrinkle severity; distinct from the Fitzpatrick skin type scale I–VI, where I is very fair and VI is deeply pigmented) across pooled trials, with single-session ablative CO2 showing the largest effect and 3–5 session fractional non-ablative protocols showing more modest gains; satisfaction rates of approximately 70–90% across surveys.

Improved Skin Texture and Tone

Controlled trials and prospective cohorts consistently report improvement in skin texture (smoothness, pore appearance, micro-relief) and tone (reduced erythema, reduced lentigines) after laser resurfacing. Mechanistic support comes from dermal collagen reorganization, epidermal turnover, and selective destruction of pigmented and vascular targets. The Sodagar et al. 2025 meta-analysis of comparative RCTs showed Er:YAG plus radiofrequency producing the highest rate of “good” or “excellent” results across rejuvenation outcomes.

Magnitude: Pooled improvement rates of approximately 49% “excellent” or “good” across comparative RCTs of laser-based rejuvenation; investigator-rated texture improvements of 1–2 points on 4–5-point standardized photo scales after a typical course.

Medium 🟩 🟩

Reduction of Photoaging-Associated Pigmentation (Lentigines and Sun Spots)

Ablative and selected non-ablative resurfacing platforms (especially 1927 nm fractional non-ablative devices) effectively reduce solar lentigines (sun-induced pigment spots) and overall mottled hyperpigmentation through selective targeting of melanin and accelerated epidermal turnover. Outcomes are most consistent in Fitzpatrick I–III skin; in higher skin types the picture is more mixed because of post-inflammatory hyperpigmentation risk.

Magnitude: 50–80% lightening of solar lentigines after a 2–4 session non-ablative fractional course at 1927 nm in published trials; greater single-session improvement with fractional ablative platforms but with higher pigmentary risk.

Improvement of Atrophic Acne Scarring

Multiple systematic reviews show that fractional ablative laser resurfacing — particularly fractional CO2 — produces clinically meaningful improvement in atrophic (depressed) acne scars, often with effects comparable to or exceeding microneedling or chemical peels. Improvement is typically partial rather than complete, and combination protocols with microneedling, subcision, or topicals are common.

Magnitude: Approximately 25–50% improvement in scar severity scores (e.g., ECCA grade — Échelle d’évaluation Clinique des Cicatrices d’Acné, a clinical acne-scar grading scale) after 3–5 sessions of fractional CO2 laser; comparable Er:YAG outcomes; approximately 30% advantage over Q-switched Nd:YAG in pooled meta-analysis.

Increased Dermal Collagen Density and Skin Elasticity

Histologic and ultrasound-based studies document increases in dermal collagen density, organized type I and III collagen, and improvements in skin elasticity after laser resurfacing. The effect is dose-dependent and persists for 6–12 months after a course; single-session ablative resurfacing produces the largest histologic change, while multi-session fractional non-ablative produces incremental cumulative gains.

Magnitude: Histologic studies report approximately 15–30% increase in dermal collagen density at 3–6 months after an ablative fractional course; cutometer-based elasticity (R2, R7) typically improves on the order of 5–15%.

Low 🟩

Reduction of Field Cancerization and Actinic Keratosis Burden

Fractional ablative laser resurfacing of heavily sun-damaged skin reduces the prevalence and recurrence of actinic keratoses (precancerous skin lesions) and may reduce the incidence of non-melanoma skin cancer in treated fields. The mechanism combines physical removal of atypical keratinocytes, recruitment of new clonal populations during re-epithelialization, and possibly altered local immune surveillance. Evidence comes from observational cohorts and ongoing randomized trials in geriatric populations; the strongest published signals are for actinic keratosis count reduction.

Magnitude: Reductions of approximately 50–80% in actinic keratosis count at 6–12 months after a single fractional ablative session in observational studies; randomized data on non-melanoma skin cancer incidence are still maturing.

Adjunctive Improvement of Skin Laxity

Ablative and fractional ablative resurfacing produce modest skin tightening through dermal collagen contraction and remodeling, useful for early-stage facial laxity but smaller than dedicated radiofrequency, ultrasound, or surgical alternatives. The Levy et al. 2025 expert consensus reports that 60% of surveyed practitioners use fractional ablative CO2 to address skin laxity in non-facial areas.

Magnitude: Subjective laxity improvement reported in roughly 50–70% of patients with mild–moderate laxity; objective changes (ultrasound dermal thickness, jowl displacement) are smaller and inconsistent across studies.

Improvement of Surgical and Traumatic Scars

Fractional CO2 and fractional non-ablative lasers improve the appearance of mature surgical and traumatic scars and may reduce hypertrophic scar formation when used early after wound closure. Effects include reductions in erythema, height, and surface irregularity.

Magnitude: Approximately 25–50% improvement in scar scales (e.g., Vancouver Scar Scale) over 3–5 sessions; greatest benefit for scars treated within the first 3–6 months.

Speculative 🟨

Long-Term Slowing of Photoaging Trajectory

Because periodic laser resurfacing repeatedly removes accumulated photoaged tissue and stimulates collagen synthesis, proponents propose that maintenance-cadence resurfacing might slow the long-term trajectory of photoaging beyond the duration of any single treatment effect. Long-term controlled trials directly testing this are lacking; the hypothesis rests on cumulative-dose extrapolation from short-term outcomes and observational follow-up.

Skin Cancer Risk Reduction Beyond Actinic Keratoses

Some clinicians and ongoing trials propose that fractional ablative resurfacing of sun-damaged fields could meaningfully reduce subsequent squamous cell carcinoma and basal cell carcinoma incidence, not just actinic keratosis precursors. Mechanistic plausibility is reasonable, and a randomized trial (NCT03906253) is actively testing this hypothesis. Until that and similar trials report definitive long-term outcomes, the skin-cancer-risk-reduction signal remains hypothesis-generating rather than established for cancer endpoints.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in collagen genes (COL1A1, which encodes the primary structural protein of skin) and matrix-remodeling genes (MMP1, which encodes the collagen-degrading enzyme), as well as antioxidant capacity (SOD2, an antioxidant enzyme; GPX1, a glutathione-peroxidase enzyme) and pigment-pathway genes (MC1R, the melanocortin-1 receptor influencing melanin production; TYR, encoding tyrosinase, the rate-limiting enzyme in melanin synthesis), influence wound-healing kinetics and pigmentary response. Routine clinical testing for these variants is not yet available but provides plausible biological grounding for inter-individual variability.

  • Baseline biomarker levels: Vitamin D status, HbA1c (glycated hemoglobin, a marker of long-term blood glucose), thyroid function (TSH, thyroid-stimulating hormone, a pituitary hormone regulating thyroid activity), and post-menopausal estrogen status correlate with baseline collagen turnover and wound-healing capacity; uncontrolled hyperglycemia and estrogen deficiency are associated with smaller observed gains and slower healing.

  • Baseline photoaging severity: Glogau II–III photoaging (visible wrinkles, pigmentary changes) shows the clearest measurable gains; very young skin with minimal damage has less room to improve, and severe photoaging (Glogau IV) often requires more aggressive (ablative or surgical) approaches to achieve clinically meaningful change.

  • Fitzpatrick skin type and skin of color: Lower Fitzpatrick types (I–III) tolerate more aggressive ablative resurfacing with lower pigmentary risk; higher Fitzpatrick types (IV–VI) generally respond better to non-ablative or carefully dosed fractional ablative protocols, and require strict pigment-modulating pre- and post-care to minimize post-inflammatory hyperpigmentation (darkening that follows inflammation).

  • Sex-based differences: Clinical trials enroll predominantly women; men with thicker dermis, more sebaceous skin, and denser facial hair may show slightly different effective doses and timecourses, but robust head-to-head sex comparisons are limited.

  • Age-related considerations: Older adults often have thinner, more fragile dermis and slower wound healing; gentler parameters and longer recovery windows are typically used. The relative benefit-to-risk ratio of laser resurfacing for actinic-keratosis reduction may actually favor older, sun-damaged populations even when cosmetic gains are smaller.

  • Smoking and inflammatory status: Current smokers and those with chronic low-grade inflammation show impaired wound healing and a higher rate of pigmentary irregularity; benefit is reliably smaller in this group.

  • Adherence to pre- and post-procedure skincare: Pre-treatment with topical retinoids, hydroquinone, and broad-spectrum sunscreen, and post-treatment with strict photoprotection and barrier-supporting topicals, materially improve outcomes; non-adherence is a strong negative modifier.

  • Device class and operator skill: Wavelength, fractionation, density, and energy settings, and the experience of the practitioner with the specific device, all materially affect outcomes — to a degree that often exceeds patient-level biological variation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Post-Procedure Erythema and Edema

Redness and swelling are universal after ablative and most fractional resurfacing procedures. The mechanism is acute inflammation and dilated dermal microvasculature in response to thermal injury. Severity and duration scale with device aggressiveness — fractional non-ablative protocols typically produce 1–3 days of mild erythema, fractional ablative protocols 5–14 days, and full-field ablative CO2 weeks of erythema. Erythema is generally expected and benign but can be distressing and can prolong social downtime.

Magnitude: Reported in essentially 100% of treated patients; mean duration approximately 12.8 days for laser combinations and 15.2 days for monotherapy in the Pour Mohammad et al. 2023 meta-analysis; can persist 3–6 months after aggressive ablative treatment in a minority of patients.

Medium 🟥 🟥

Post-Inflammatory Hyperpigmentation

Darkening at treatment sites — driven by stimulated melanocyte activity in the inflamed dermis and epidermis — is the most common pigmentary complication, particularly in Fitzpatrick III–VI skin. Mechanism is melanogenesis triggered by inflammation. Topical pre- and post-care with hydroquinone, retinoids, and strict photoprotection materially reduces but does not eliminate the risk.

Magnitude: Reported in approximately 5–15% of fractional non-ablative cases in mixed populations; approximately 20–40% in higher Fitzpatrick types receiving more aggressive fractional ablative protocols; usually fades over 1–6 months.

Acneiform Eruptions and Milia

Small inflammatory papules and pustules (acneiform breakouts) and milia (small white epidermal cysts) commonly develop in the days to weeks after resurfacing, particularly in acne-prone skin. Mechanism includes occlusion from post-procedure ointments, altered follicular openings, and shifts in surface microbiome. Milia reflect entrapment of keratin during re-epithelialization.

Magnitude: Acneiform eruptions in approximately 10–20% of patients; milia in 5–15%; usually self-limited or treated with light extraction or topical therapy.

Reactivation of Herpes Simplex Virus

Thermal injury and barrier disruption can reactivate latent herpes simplex virus (HSV, the virus that causes cold sores) along treated skin, occasionally producing widespread cutaneous outbreaks. Antiviral prophylaxis is standard practice for facial resurfacing — over 90% of expert panelists in the Levy et al. 2025 consensus prescribe perioperative antivirals (e.g., valacyclovir).

Magnitude: Reported in approximately 0.3–7% with antiviral prophylaxis; up to 10–14% without; can produce diffuse, scarring outbreaks if untreated.

Low 🟥

Bacterial and Candidal Infection

Disrupted barrier function during re-epithelialization can permit bacterial (most commonly Staphylococcus aureus) and candidal (yeast) infection. Mechanism is breach of the epidermal barrier in a moist post-procedure environment. Topical and systemic prophylaxis is debated; the Levy et al. 2025 consensus reports >90% bacterial prophylaxis use but only 33% antifungal prophylaxis.

Magnitude: Bacterial infection in approximately 0.5–4% of cases; candidal infection in up to 2%; usually resolves with appropriate antimicrobial therapy.

Hypopigmentation

Loss of pigment in treated skin — generally a late complication appearing months to years after aggressive ablative resurfacing — reflects melanocyte injury and reduced melanin production. This is the historical Achilles heel of full-field CO2 resurfacing and a key reason for its decline in favor of fractional platforms.

Magnitude: Approximately 5–20% with full-field ablative CO2 in Fitzpatrick I–III; approximately 1–3% with fractional ablative protocols; rare with fractional non-ablative; often permanent.

Scarring

Hypertrophic (raised) or atrophic (depressed) scarring is uncommon but can occur with overly aggressive parameters, repeated treatment of the same site before healing, or infection. Mechanism is excessive thermal injury or disrupted wound healing. Risk is materially elevated in patients on isotretinoin (a systemic retinoid), with active infection, or with personal or family history of keloid scarring.

Magnitude: Reported in approximately 0.3–1% of fractional resurfacing procedures and approximately 1–3% of full-field ablative; higher in mid- to lower-face anatomically and in patients with predisposing factors.

Prolonged Erythema Beyond Expected Course

Erythema persisting beyond the expected window (more than 1 month for fractional non-ablative, more than 3 months for fractional ablative) can occur and reflects ongoing dermal inflammation or vascular response. Most cases resolve over additional months with topical and pulsed-dye-laser intervention.

Magnitude: Reported in approximately 1–10% depending on device class; usually resolves within 6 months.

Periorbital Eye Injury Without Eye Protection

Direct or scattered laser energy can damage corneal and retinal tissue; metal corneal shields (or external eye-protection goggles for non-ocular field) are standard during periocular treatment. Mechanism is direct photonic absorption by ocular structures.

Magnitude: Rare with proper eye protection; documented case reports of corneal abrasion and uveitis with inadequate shielding.

Speculative 🟨

Long-Term Effects of Repeated High-Cumulative-Dose Resurfacing

The cumulative effect of multiple resurfacing courses across decades — particularly aggressive fractional ablative cycles — on long-term skin barrier function, photoprotection, and cancer risk is not well characterized. This is a gap in the evidence rather than a known harm signal.

Theoretical Skin Cancer Risk in Pre-Existing Dysplastic Lesions

Because thermal injury can mask or alter the appearance of cutaneous lesions, treating skin fields without prior dermatologic evaluation could theoretically delay diagnosis of melanoma or other cutaneous malignancies. Systematic review evidence does not show that resurfacing itself induces malignancy, but the diagnostic-delay concern remains.

Risk-Modifying Factors

  • Genetic polymorphisms: Pigment-pathway variants (MC1R, TYR — the receptor and rate-limiting enzyme governing melanin production) modify post-inflammatory hyperpigmentation risk; collagen-related variants influence scar formation; porphyria-related heme-synthesis gene variants raise photosensitivity. Clinically actionable resurfacing-specific genetic testing is not established.

  • Baseline biomarker levels: Uncontrolled HbA1c (glycated hemoglobin, reflecting average blood glucose), low vitamin D, and elevated inflammatory markers correlate with slower healing and higher complication rates; baseline melanin activity (e.g., active melasma — a pigmentation disorder driven by melanocyte overactivity) is itself a marker of higher pigmentary risk.

  • Fitzpatrick skin type (especially IV–VI): Higher skin types carry materially increased post-inflammatory hyperpigmentation risk; the Levy et al. 2025 expert consensus reports that >90% of surveyed practitioners adjust fractional CO2 settings for Fitzpatrick III–IV skin, and many defer aggressive ablative resurfacing in Fitzpatrick V–VI to dedicated specialists.

  • Active acne, rosacea, or other inflammatory skin disease: Increases risk of breakouts, prolonged erythema, and irregular healing; stabilization is generally pursued before resurfacing.

  • Active or recent herpes simplex outbreaks: Strongly elevate the risk of post-procedure HSV reactivation; antiviral prophylaxis is standard, and active cold sores are an absolute contraindication to treatment over the affected area.

  • Recent or current isotretinoin use: Oral isotretinoin produces a fragile epidermis and impaired wound healing; many practitioners traditionally defer resurfacing during and for ≥6 months after a course, although recent evidence has questioned the rigidity of that interval for fractional non-ablative platforms.

  • Photosensitizing medications: Tetracyclines (a class of antibiotics such as doxycycline), fluoroquinolones (antibiotics such as ciprofloxacin), sulfonamides, amiodarone (an antiarrhythmic), voriconazole (an antifungal), and hydrochlorothiazide (a diuretic) raise sensitivity and complication risk.

  • Pregnancy and breastfeeding: The Levy et al. 2025 expert consensus identifies pregnancy and breastfeeding as a relative contraindication, although the underlying evidence for harm to the fetus or infant is minimal; practitioners typically defer elective aesthetic resurfacing.

  • Recent sun exposure: Tan or freshly sun-exposed skin elevates post-inflammatory hyperpigmentation risk; the Levy et al. 2025 consensus identifies recent sun exposure as a contraindication for 67% of expert panelists.

  • History of keloid or hypertrophic scarring: Personal or family history materially elevates scarring risk; non-facial body areas are especially affected.

  • Active autoimmune skin disease (e.g., lupus, vitiligo, scleroderma): Active or recent flares are typically considered a contraindication; stable disease may permit gentler protocols under specialist guidance.

  • Sex-based considerations: Trial populations skew female; men may experience slightly higher acneiform eruption rates due to denser sebaceous glands, but specific differences are limited.

  • Age-related factors: Older adults often have thinner, more vascular skin and slower healing; gentler parameters and longer recovery windows are typical.

Key Interactions & Contraindications

  • Photosensitizing prescription drugs: Tetracyclines (e.g., doxycycline, minocycline), fluoroquinolones (e.g., ciprofloxacin, levofloxacin), sulfonamides (e.g., sulfamethoxazole), amiodarone, voriconazole, hydrochlorothiazide, and phenothiazines. Severity: caution; consider deferring elective treatment. Consequence: exaggerated erythema, prolonged healing, post-inflammatory hyperpigmentation. Mitigation: discontinue or substitute where clinically possible for ≥1 week pre-procedure and during the healing window.

  • Oral isotretinoin (a systemic retinoid): Severity: traditionally a relative contraindication for ≥6 months after a course, although some recent evidence supports earlier fractional non-ablative use. Consequence: fragile epidermis, impaired healing, increased scarring risk. Mitigation: defer aggressive ablative protocols; consult dermatology for fractional non-ablative timing.

  • Anticoagulants and antiplatelet medications: Warfarin, direct oral anticoagulants (DOACs, e.g., apixaban, rivaroxaban), aspirin, clopidogrel. Severity: monitor. Consequence: increased post-procedure bruising and pinpoint bleeding. Mitigation: many practitioners do not require discontinuation for fractional resurfacing; aspirin and herbal anticoagulants may be paused 7–10 days pre-procedure if not medically essential.

  • Topical actives (retinoids, alpha and beta hydroxy acids, benzoyl peroxide, hydroquinone): Severity: monitor. Consequence: heightened irritation if continued through procedure window; reduced post-inflammatory hyperpigmentation risk if used appropriately pre-procedure. Mitigation: typical protocols pause topical actives 5–7 days before and 7–14 days after resurfacing; pre-procedure hydroquinone and retinoid priming protocols are common.

  • Antivirals (prophylactic): Valacyclovir or acyclovir is routinely co-prescribed for facial resurfacing. Severity: prophylactic. Consequence (without): HSV reactivation. Mitigation: standard practice is valacyclovir 500 mg twice daily starting 1–2 days before procedure and continuing 7–10 days after.

  • Antibiotics and antifungals (prophylactic): Bacterial prophylaxis (e.g., a first-generation cephalosporin or azithromycin) is used by most experts; antifungal prophylaxis is selectively used. Severity: monitor. Consequence (without): bacterial or candidal superinfection. Mitigation: device- and protocol-specific.

  • Photosensitizing supplements and topicals: St. John’s wort (an herbal supplement used for mood support; a known photosensitizer), bergamot oil, and porphyrin precursors used in photodynamic contexts. Severity: caution. Consequence: phototoxicity. Mitigation: pause for ≥1 week before procedure.

  • Adjacent aesthetic interventions: Sequential combination with neuromodulators (botulinum toxin), hyaluronic acid fillers, microneedling, intense pulsed light (IPL), and chemical peels is common; the Levy et al. 2025 expert consensus reports 81% of panelists use supplementary treatment to maximize results, including neuromodulators (76%), IPL (61%), and injectable fillers (48%). Severity: monitor. Consequence: over-treatment, prolonged erythema if stacked too tightly. Mitigation: separate higher-intensity procedures from resurfacing by 2–4 weeks unless protocol-specific.

  • Populations who should avoid or defer treatment:

    • Individuals with active facial infection (bacterial, viral, fungal) — identified as a contraindication by 95% of expert panelists.
    • Individuals with active herpes simplex outbreak in or near the treatment field.
    • Individuals with recent severe sun exposure or current sunburn — identified as a contraindication by 67% of expert panelists.
    • Individuals with active cutaneous malignancy in the treatment field, until evaluated by a dermatologist or oncologist.
    • Individuals on active oral isotretinoin therapy and within 6 months of a completed course (traditional rule), particularly for ablative protocols.
    • Pregnant or breastfeeding individuals (relative contraindication — identified by 67% of expert panelists).
    • Individuals with active autoimmune skin disease (e.g., systemic lupus erythematosus — an autoimmune disease that can be triggered or worsened by light, with active CLASI — Cutaneous Lupus Erythematosus Disease Area and Severity Index activity score >1; active scleroderma; active vitiligo).
    • Individuals with active porphyria (a group of disorders of heme synthesis associated with severe photosensitivity), including porphyria cutanea tarda and erythropoietic protoporphyria.
    • Individuals with personal or strong family history of keloid scarring (relative contraindication — non-facial body sites particularly affected).
    • Individuals with realistic skin-type-specific risk concerns (e.g., Fitzpatrick V–VI for full-field ablative resurfacing) without access to a clinician experienced in skin of color.

Risk Mitigation Strategies

  • Pre-procedure hydroquinone and retinoid priming: Apply hydroquinone 4% nightly with a topical retinoid for 4–6 weeks before the procedure (especially in Fitzpatrick III–VI). Mitigates: post-inflammatory hyperpigmentation by suppressing baseline melanogenesis and accelerating epidermal turnover.

  • Strict photoprotection 4 weeks before and 12 weeks after: Daily broad-spectrum SPF 30+ sunscreen, sun-avoidance during peak hours, and wide-brimmed hats. Mitigates: pigmentary disturbance and hindered healing from UV exposure to vulnerable post-procedure skin.

  • Antiviral prophylaxis for facial resurfacing: Valacyclovir 500 mg twice daily (or 1 g twice daily for prior outbreak history) starting 1–2 days before procedure and continuing 7–10 days after. Mitigates: herpes simplex reactivation, which can otherwise produce diffuse scarring outbreaks.

  • Bacterial prophylaxis where indicated: A short course of an oral antibiotic (e.g., cephalexin 500 mg four times daily or azithromycin 500 mg daily for 5 days) is used by most experts for ablative and aggressive fractional ablative procedures. Mitigates: bacterial superinfection of disrupted barrier.

  • Test spots in higher Fitzpatrick types and sensitive skin: A 1–2 cm test area treated 4–6 weeks ahead of full treatment, observed for pigmentary response. Mitigates: unexpected post-inflammatory hyperpigmentation in higher skin types.

  • Conservative parameters in higher skin types: Lower fluence, lower density, and more sessions instead of single aggressive treatments. Mitigates: pigmentary complications. The Levy et al. 2025 expert consensus reports >90% of surveyed practitioners adjust settings for Fitzpatrick III–IV.

  • Smoking cessation 4 weeks pre- and post-procedure: Mitigates: impaired wound healing, elevated infection rate, and prolonged erythema associated with active smoking.

  • Avoid aggressive resurfacing on or around isotretinoin therapy: Defer ablative and aggressive fractional ablative protocols during and for ≥6 months after an isotretinoin course (traditional rule); fractional non-ablative protocols may be considered earlier with specialist guidance. Mitigates: scarring and impaired healing.

  • Eye protection: Metal corneal shields for periocular ablative work; external eye-protection goggles for adjacent fields. Mitigates: corneal injury and retinal phototoxicity.

  • Strict aftercare regimen: Petrolatum or specialty post-procedure ointments for ablative cases, dilute vinegar or saline soaks as instructed, gentle cleansers, no makeup until re-epithelialization is complete, no exfoliating actives until barrier is restored. Mitigates: infection, prolonged inflammation, and pigmentary complications.

  • Reassess at 8–12 weeks and 6 months: Standardized photography at each timepoint with side-by-side comparison. Mitigates: unrecognized hypopigmentation, persistent erythema, or absent benefit.

  • Avoid treating over suspect lesions: Have any new, changing, or unexplained pigmented or growing lesion evaluated by a dermatologist before resurfacing. Mitigates: delayed diagnosis of skin cancer that could be masked by treatment-induced inflammation.

Therapeutic Protocol

A standard skin-rejuvenation protocol typical of dermatology and plastic-surgery practitioners (e.g., academic dermatology groups such as the University of Pittsburgh’s UPMC Cosmetic Surgery and Skin Health Center under Suzan Obagi, M.D., the FACE Institute in Austin under Tanuj Nakra, M.D., and the Wellman Center for Photomedicine where fractional photothermolysis was developed) combines:

  • Device class selection: Tailored to skin type, photoaging severity, and acceptable downtime. Common platforms include fractional non-ablative 1550 nm/1927 nm (Fraxel re:store, Fraxel Dual), fractional ablative 2940 nm Er:YAG (Sciton Halo, Lutronic Action II), fractional ablative 10,600 nm CO2 (Lumenis UltraPulse, Solta Fraxel re:pair, Lutronic eCO2), and full-field ablative CO2 (reserved for severe photoaging in Fitzpatrick I–III).
  • Density and depth: Density (treatment coverage per pass, typically 5–40%) and depth (column depth, typically 200–1,500 μm) are selected for the target indication. Higher density and depth produce larger effect with longer recovery.
  • Pulse energy/fluence: Typically 5–70 mJ per microbeam for fractional ablative platforms; 4–70 mJ per microbeam for fractional non-ablative.
  • Number of passes: 1–4 passes per session, with overlap minimized to avoid bulk thermal injury.
  • Session length: Approximately 20–60 minutes per face, including pre-procedure topical anesthesia (95% of experts use topical anesthetic, 81% use nerve blocks, 62% use oral analgesics, per Levy et al. 2025).
  • Course structure: Single session for full-field ablative (every 5+ years per Soleymani’s framing on the Huberman Lab podcast); 1–3 sessions for fractional ablative spaced 4–8 weeks apart; 3–5 sessions for fractional non-ablative spaced 2–6 weeks apart, often with annual maintenance.

Competing therapeutic approaches include:

  • Conventional aesthetic dermatology: centers laser resurfacing as a definitive resurfacing modality in a regimen alongside topical retinoids, vitamin C, and broad-spectrum sunscreens. Leading academic groups (e.g., UPMC Cosmetic Surgery and Skin Health Center under Suzan Obagi, M.D. — an academic clinical practice whose affiliated faculty derive revenue from both performing aesthetic procedures and from device-industry research and consulting; and the FACE Institute under Tanuj Nakra, M.D. — a private fellowship and research institute in Austin, Texas with similar dual revenue streams) frame laser resurfacing as a foundational or step-up procedure depending on baseline photoaging.
  • Integrative and longevity-oriented practice: tends to position laser resurfacing as one of several available aesthetic interventions, prioritized after foundational sun protection, retinoid use, glycemic control, sleep, and nutrition. This framing is reflected in episodes from Peter Attia (with Tanuj Nakra and Suzan Obagi) and Andrew Huberman (with Teo Soleymani) and in commentary from longevity-oriented dermatologists.
  • Less aggressive or substitutive aesthetic modalities: chemical peels, microneedling with or without radiofrequency, intense pulsed light, and at-home photobiomodulation (low-level red and near-infrared light therapy) are alternatives or adjuncts; the Sodagar et al. 2025 meta-analysis suggests Er:YAG plus radiofrequency outperforms most rejuvenation alternatives, while microneedling and IPL produce smaller effect sizes than laser resurfacing for wrinkle endpoints.

None of these approaches should be framed as the default; they differ in cost, recovery, evidence threshold, and goals.

  • Best time of day: No strong evidence that time of day affects outcomes. Most practices schedule morning to mid-day to allow full post-procedure care implementation before sleep and to minimize same-day UV exposure.

  • Pharmacological properties (half-life, split dosing): Laser resurfacing is not a pharmacological agent and has no half-life or split-dose considerations in the pharmacokinetic sense. Biologically, the wound-healing and remodeling cascade peaks at 1–6 months and continues for up to 12 months, supporting course spacing of 4–8 weeks rather than tighter intervals.

  • Pharmacogenetic and polymorphism considerations: No validated pharmacogenetic markers determine response to laser resurfacing. Pigment-pathway variants (MC1R, TYR — coding for the melanocortin-1 receptor and tyrosinase) influence pigmentary risk; collagen and matrix-remodeling variants (COL1A1, MMP1 — coding for type I collagen and a collagen-degrading enzyme) plausibly influence dermal response, but clinically actionable testing is not available.

  • Sex-based differences in response: Clinical trials enroll predominantly women; recommendations are best validated in female facial skin. Men with thicker dermis and denser facial hair may require slightly different parameters and often experience higher acneiform eruption rates; head-to-head comparisons are limited.

  • Age-related considerations: Older adults often need gentler parameters and longer recovery windows due to thinner dermis and slower healing; the relative benefit-to-risk ratio for actinic-keratosis reduction may favor older sun-damaged populations.

  • Baseline biomarkers influencing response: No specific biomarker is required before resurfacing, but practitioners often check vitamin D status, HbA1c (glycated hemoglobin, a marker of average blood glucose), thyroid function, and post-menopausal estrogen status because addressing these can amplify response and accelerate healing.

  • Pre-existing conditions affecting response: Active acne or rosacea, active melasma, current smoking, uncontrolled diabetes (HbA1c >7%), and active autoimmune skin disease are associated with poorer or less predictable responses and warrant stabilization before a course.

  • Pre-procedure priming: Hydroquinone and retinoid priming (typically 4–6 weeks pre-procedure in Fitzpatrick III–VI), strict photoprotection, smoking cessation, and topical-active discontinuation 5–7 days pre-procedure are standard.

  • Anesthesia choice: Topical anesthetic alone for non-ablative protocols; topical plus nerve block for fractional ablative; topical plus nerve block plus oral analgesia (and occasionally light intravenous sedation) for full-field ablative.

Discontinuation & Cycling

  • Lifelong vs. short-term: Laser resurfacing is generally administered as discrete courses rather than continuous therapy. Course spacing typically reflects device class — single-session full-field ablative every 5+ years, 1–3 fractional ablative sessions every 1–3 years, and 3–5 fractional non-ablative sessions annually or biannually.

  • Withdrawal effects: No physiological withdrawal effects from stopping resurfacing courses. Visible cosmetic benefit gradually attenuates as ongoing photoaging proceeds, typically over 1–3 years for fractional non-ablative gains and 3–5+ years for ablative gains, depending on sun exposure and skincare adherence.

  • Tapering-off protocol: No formal taper. A practical stepdown is to reduce session frequency over time and rely more heavily on topical retinoids, sunscreens, and at-home photobiomodulation for maintenance.

  • Cycling for efficacy: The standard pattern is course-then-maintenance rather than continuous treatment. Some practitioners use periodic single-session fractional non-ablative “tune-ups” between full courses; this is pragmatic rather than evidence-driven.

  • Sequencing across decades: A common longitudinal pattern in cosmetic dermatology is fractional non-ablative in the 30s and 40s, fractional ablative in the 40s–60s, and full-field ablative reserved for severe photoaging or as an alternative to surgical lifting in later decades; this is a clinical-practice convention rather than a rigorously trial-tested schedule.

Sourcing and Quality

  • Practitioner credentials: Look for board-certified dermatologists, plastic surgeons, or facial plastic surgeons with specific fellowship training or extensive experience in laser surgery; certification through bodies such as the American Board of Dermatology, American Board of Plastic Surgery, American Society for Laser Medicine and Surgery, or American Society for Dermatologic Surgery is standard.

  • Device manufacturers and platforms: Reputable platforms with substantial published clinical literature include Solta Medical (Fraxel re:store, re:pair, FTX), Lumenis (UltraPulse, AcuPulse), Lutronic (eCO2, Action II), Sciton (ProFractional, Halo, MicroLaserPeel), Cynosure (Icon, SmartSkin), and Candela (CO2RE). FDA 510(k) clearance for the relevant intended use is the regulatory baseline; clearance signals review of safety and substantial-equivalence claims rather than demonstrated efficacy beyond the comparator device.

  • Practice-setting considerations: Procedures performed in dermatology, plastic surgery, or facial plastic surgery offices with on-site emergency support are generally preferred over medical-spa settings without physician oversight; complication management materially differs.

  • Pre-procedure consultation quality: A high-quality consultation includes Fitzpatrick skin type assessment, full-face photographic baseline, written pre-procedure instructions, medication review (including isotretinoin, anticoagulants, photosensitizers), explicit discussion of pigmentary risks for higher Fitzpatrick types, and a documented plan for adverse-event management.

  • Regional regulation: Practitioner scope-of-practice rules vary widely across U.S. states and across countries; some jurisdictions allow non-physician laser operators, while others restrict aggressive ablative resurfacing to physicians. Verifying the operator’s training and the supervisory arrangement is part of due diligence.

  • Avoiding aggressive marketing claims: Devices and practices promoting “one-treatment 20-year results” or “no-downtime ablative resurfacing” should be evaluated skeptically; most peer-reviewed effect sizes are more modest and most ablative procedures do involve meaningful downtime.

Practical Considerations

  • Time to effect: Initial visible erythema and edema are immediate; clinical improvement begins to emerge as re-epithelialization completes (5–14 days for fractional ablative, 1–3 weeks for full-field ablative, 1–7 days for fractional non-ablative). Full effect on wrinkles, texture, and pigmentation typically becomes apparent at 3 months and continues to improve up to 12 months as collagen remodeling matures.

  • Common pitfalls: Underestimating downtime, particularly for fractional ablative or full-field ablative procedures; non-adherence to photoprotection, leading to post-inflammatory hyperpigmentation; aggressive treatment in higher Fitzpatrick types without skin-type-appropriate priming; combining resurfacing too tightly with other intense aesthetic interventions; expectation mismatch (e.g., expecting ablative-equivalent results from fractional non-ablative); skipping antiviral prophylaxis; use of a poorly trained operator at a medical spa for an aggressive ablative procedure; and treating undiagnosed lesions before dermatology evaluation.

  • Regulatory status: Laser resurfacing devices are FDA-cleared (510(k)) for specific cosmetic indications including wrinkles, photodamage, and acne scarring. Off-label use (e.g., for actinic keratoses or non-melanoma skin cancer prevention) is common and subject to standard practice-of-medicine norms. Most rejuvenation indications are considered cosmetic and not covered by insurance.

  • Payer incentives and structural bias: Because most laser resurfacing for skin rejuvenation is paid out of pocket and not reimbursed by insurers, payers have no direct financial stake in adoption — but also no incentive to fund neutral comparative-effectiveness trials against alternatives such as topical retinoids, microneedling, or surgical lifting. Most clinical research is therefore funded by device manufacturers (Solta Medical/Bausch Health, Lumenis, Lutronic, Sciton, Cynosure, Candela), whose commercial success depends on positive outcomes, and by professional dermatology and plastic-surgery groups whose members derive direct revenue from performing the procedures. Where laser resurfacing competes with reimbursable medical-dermatology indications (e.g., field treatment of actinic keratoses), institutional payers may have an incentive to favor cheaper topicals over more expensive laser procedures, an additional source of structural bias.

  • Cost and accessibility: In the U.S., fractional non-ablative resurfacing typically costs US$1,000–$2,500 per session with packages of 3–5 sessions; fractional ablative resurfacing US$1,500–$4,000 per session; full-field ablative CO2 resurfacing US$3,000–$7,000+ per single session including facility and anesthesia. Costs are roughly half in many parts of Europe and significantly lower in some Asian and Latin American medical-tourism settings, although quality-control and follow-up considerations vary. Accessibility is broad in major U.S. and European cities but narrower in rural areas and in jurisdictions where ablative resurfacing is restricted to physicians.

Interaction with Foundational Habits

  • Sleep: Adequate sleep (typically 7–9 hours nightly) supports wound healing and reduces post-procedure erythema duration; direction is potentiating. Mechanism includes optimized growth-hormone secretion overnight and reduced systemic inflammation. Practical consideration: prioritize sleep during the 1–4 weeks of post-procedure healing; avoid alcohol and late-evening meals that can worsen swelling.

  • Nutrition: Adequate protein intake (supplying amino acids for collagen synthesis), vitamin C (an essential cofactor for collagen cross-linking), zinc, and copper support the dermal-remodeling cascade; direction is potentiating. Chronically high sugar intake — which accelerates advanced glycation end-product (AGE, a damaging sugar–protein crosslink) formation — may blunt collagen-remodeling outcomes; direction is blunting. Active smoking and heavy alcohol use are independently associated with poorer outcomes. Practical consideration: optimize protein and micronutrient status alongside a course; avoid alcohol for 48 hours pre-procedure and during the inflammatory phase.

  • Exercise: Regular cardiovascular and resistance exercise improves cutaneous microcirculation and metabolic health, indirectly supporting healing; direction is potentiating long-term. Vigorous exercise during the immediate post-procedure inflammatory phase (typically the first 5–7 days) can worsen erythema and edema; direction is blunting acutely. Practical consideration: defer intense workouts for 5–7 days after fractional ablative and 2–3 weeks after full-field ablative; light walking is acceptable.

  • Stress management: Chronic stress elevates cortisol and impairs wound healing; direction is blunting. There is no evidence that laser resurfacing itself meaningfully alters stress physiology. Practical consideration: schedule procedures during periods with predictable rest and reduced obligations; practitioners on the Peter Attia and Huberman Lab episodes referenced above emphasize the psychological as well as biological component of cosmetic procedures.

Monitoring Protocol & Defining Success

Baseline assessment centers on standardized photography, Fitzpatrick skin typing, photoaging grading, and a focused medical and medication review before starting a course, so changes can be objectively tracked over time and risk factors addressed in advance.

Ongoing monitoring typically includes wound-care follow-up at 1 week (re-epithelialization check), 4 weeks (early outcome and complication review), 3 months (primary efficacy check), and 6–12 months (sustained outcome, with photographs at each timepoint).

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Standardized before/after facial photography Consistent lighting, angle, and expression across timepoints Objective visual benchmark for wrinkle, texture, and pigmentation change Use the same device, neutral lighting, and no makeup; capture at baseline, 1, 4, 12, and 26 weeks.
Fitzpatrick skin type (I–VI) I describes very fair skin that always burns; VI describes deeply pigmented skin that rarely burns Anchors device-class and parameter selection Should be assessed at baseline; affects pigmentary risk profile.
Glogau photoaging scale (I–IV) Improvement by at least 1 category at 12 weeks Structured clinical grading of photoaging I describes mild, no wrinkles; IV describes severe wrinkles throughout. Rater-dependent.
Fitzpatrick wrinkle and elastosis scale Improvement by at least 1 point at 12 weeks Scale specifically targeted at wrinkle severity Used widely in resurfacing trials; best paired with photography.
Cutometer-based elasticity (R2, R7) R2 above 0.70 in adult facial skin (functional target); improvement from baseline Objective measure of skin elasticity Available in specialized clinics; useful for serial measurements.
Skin hydration (corneometry) Site-specific baseline; stable or improving Tracks barrier integrity during recovery Changes can signal over-treatment or barrier dysfunction.
Vitamin D, 25-OH 40–60 ng/mL (functional) Overall skin and wound-healing context 25-OH is 25-hydroxyvitamin D, the main circulating form of vitamin D. Conventional reference range often 30–100 ng/mL; fasting not required.
Ferritin 50–150 ng/mL (functional) Iron status supports collagen synthesis and healing Ferritin is the iron-storage protein and reflects iron stores. Conventional reference extends higher; inflammation can falsely elevate it.
Fasting glucose and HbA1c Fasting glucose 70–90 mg/dL; HbA1c below 5.4% (functional) Elevated glucose accelerates AGE formation, impairs healing, and worsens post-procedure infection risk HbA1c is glycated hemoglobin and reflects 3-month average blood glucose. Fasting glucose requires overnight fast; HbA1c does not.
Thyroid-stimulating hormone (TSH) 0.5–2.5 mIU/L (functional) Thyroid status influences skin turnover and wound healing TSH is a pituitary hormone regulating thyroid function; conventional reference range often up to 4.5 mIU/L; best measured early morning.
Estradiol and testosterone (in relevant contexts) Individualized Sex hormones shape dermal collagen content, especially post-menopause Timing matters in menstruating women; fasting not required.
Total full-body skin examination by a dermatologist No suspicious or undiagnosed lesions in the planned treatment field Avoids treating over occult skin cancer or precancerous lesions Should occur within 6 months of any aggressive resurfacing in sun-damaged skin.

Qualitative markers are tracked alongside the objective measures:

  • Subjective smoothness, “glow,” and texture self-rating.
  • Makeup behavior (even application, reduced settling in fine lines).
  • Daytime redness, reactivity, and barrier comfort.
  • Sleep quality during recovery (worsening sleep can prolong erythema).
  • Emotional response to the recovery period (transient self-image effects during peeling and erythema phases are common and worth tracking).
  • New or changing pigmented lesions in or near the treatment field — any new lesion should prompt dermatology evaluation rather than re-treatment.

Emerging Research

Conclusion

Laser resurfacing is a clinic-administered procedure that uses focused beams of light to ablate or heat the upper layers of the skin, prompting collagen remodeling and epidermal renewal. The strongest human evidence supports meaningful reductions in fine lines and wrinkles, improvements in skin texture and tone, and improvement of depressed acne scarring and sun-induced pigment spots. Fractional ablative platforms produce the largest single-course effect on photoaging, while fractional non-ablative platforms produce smaller but cumulative effects with shorter recovery. Effects are dose-dependent and persist months to years.

Safety has improved markedly with the shift from full-field to fractional devices, but the procedure remains an inflammatory injury whose risks scale with aggressiveness. Common short-term effects include redness, swelling, and breakouts; the most clinically important risks are darkening of treated skin (especially in higher skin tones), cold-sore reactivation, infection, loss of pigment, and rare scarring. Strict pre- and post-procedure skincare, antiviral prophylaxis, and operator skill materially shape the outcome.

The evidence base is large but uneven. Most of the research has been produced or funded by laser device manufacturers and by professional dermatology and plastic-surgery groups whose members derive direct revenue from performing the procedures, a structural conflict that colors guidelines and effect-size estimates. For an audience invested in skin health as part of a longevity strategy, laser resurfacing is one well-developed option in a layered regimen that begins with sun protection, retinoids, glycemic control, sleep, and nutrition; whether to add it depends on baseline skin, downtime tolerance, skin tone, and practitioner experience.

Top - Benefits - Risks - Protocol